Abstract |
In a double-blind, parallel-group, multicenter, comparative trial in 120 evaluable patients with chronic, localized atopic dermatitis or lichen simplex chronicus, the success rate (described as "healed" and "marked improvement") was 91.5% in patients treated with halobetasol propionate ointment and 83.6% in those in the diflucortolone valerate treatment group. Of patients treated with halobetasol propionate ointment, 40.7% reported healing within 17 days, whereas of those in the diflucortolone valerate treatment group, 32.8% reported healing within that time. Early onset of therapeutic effect, that is, within 3 days of the start of treatment, was reported in a higher percentage of patients treated with halobetasol propionate ointment than in those treated with diflucortolone valerate ointment (70% versus 59%). Adverse effects at the site of application were less frequently reported in patients belonging to the halobetasol propionate treatment group than in those treated with diflucortolone valerate ointment (3% versus 8%).
|
Authors | N Brunner, S Yawalkar |
Journal | Journal of the American Academy of Dermatology
(J Am Acad Dermatol)
Vol. 25
Issue 6 Pt 2
Pg. 1160-3
(Dec 1991)
ISSN: 0190-9622 [Print] United States |
PMID | 1757609
(Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Ointments
- Vasoconstrictor Agents
- diflucortolone valerate
- halobetasol
- Clobetasol
- Diflucortolone
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Austria
- Chronic Disease
- Clobetasol
(administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
- Dermatitis, Atopic
(drug therapy)
- Diflucortolone
(administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
- Neurodermatitis
(drug therapy)
- Ointments
- Patient Satisfaction
- Remission Induction
- Vasoconstrictor Agents
(administration & dosage, adverse effects, therapeutic use)
- Wound Healing
|